학술논문
The Progressive Supranuclear Palsy Clinical Deficits Scale
Document Type
article
Author
Piot, Ines; Schweyer, Kerstin; Respondek, Gesine; Stamelou, Maria; Sckopke, Philipp; Schenk, Thomas; Goetz, Christopher G; Stebbins, Glenn T; Höglinger, Günter U; Gasser, Thomas; Hermann, Andreas; Höglinger, Günter; Höllerhage, Matthias; Kimmich, Okka; Klockgether, Thomas; Levin, Johannes; Machetanz, Gerrit; Osterrath, Antje; Palleis, Carla; Prudlo, Johannes; Spottke, Annika; Berg, Daniela; Bürk, Katrin; Claßen, Joseph; Eggers, Carsten; Greuel, Andrea; Grimm, Max‐Joseph; Hermann, Lennard; Iankova, Vassilena; Jahn, Klaus; Jost, Wolfgang; Klietz, Martin; Kühn, Andrea; Marxreiter, Franz; Paschen, Steffen; Poetter‐Nerger, Monika; Preisl, Marie‐Therese; Prilop, Lisa; Tönges, Lars; Trenkwalder, Claudia; Warnecke, Tobias; Wegner, Florian; Winkler, Jürgen; Antonini, Angelo; P, Kailash P; L, Adam L; Colosimo, Carlo; Compta, Yaroslau; Corvol, Jean‐Christophe; I, Lawrence I; E, Anthony E; Litvan, Irene; R, Huw R; Nilsson, Christer; Pantelyat, Alexander
Source
Movement Disorders. 35(4)
Subject
Language
Abstract
BackgroundThere is currently no undisputed, validated, clinically meaningful measure for deficits in the broad spectrum of PSP phenotypes.ObjectiveTo develop a scale to monitor clinical deficits in patients with PSP across its broad phenotypes.MethodsThe Progressive Supranuclear Palsy Clinical Deficits Scale was conceptualized to cover seven clinical domains (Akinesia-rigidity, Bradyphrenia, Communication, Dysphagia, Eye movements, Finger dexterity, and Gait & balance), each scored from 0 to 3 (no, mild, moderate, or severe deficits). User guidelines were developed to standardize its application. Progressive Supranuclear Palsy Clinical Deficits Scale scores were collected in patients fulfilling the MDS-PSP diagnostic criteria in two independent, multicenter, observational studies, both cross-sectionally (exploratory DescribePSP cohort; confirmatory ProPSP cohort) and longitudinally (12-months' follow-up, both cohorts).ResultsCognitive pretesting demonstrated easy scale utility. In total, 164 patients were scored (70.4 ± 7.6 years; 62% males, 35% variant phenotypes). Mean Progressive Supranuclear Palsy Clinical Deficits Scale completion time was 4 minutes. The Progressive Supranuclear Palsy Clinical Deficits Scale total score correlated with existing scales (e.g., Progressive Supranuclear Palsy Rating Scale: R = 0.88; P